Author + information
- Received June 15, 2018
- Revision received October 4, 2018
- Accepted October 18, 2018
- Published online April 1, 2019.
- aDivision of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota
- bDivision of Cardiology, Columbia University Medical Center, New York, New York
- cDivision of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
- ↵∗Address for correspondence:
Dr. Allison K. Cabalka, Division of Pediatric Cardiology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
Tricuspid valve abnormalities in congenital heart disease comprise a wide spectrum, with the most common being Ebstein anomaly and tricuspid valve dysplasia. Tricuspid valve dysfunction may also be secondary to other types of congenital heart disease, including functional tricuspid regurgitation seen in right heart volume overload conditions, such as atrial septal defect and repaired tetralogy of Fallot with severe pulmonary valve regurgitation. Congenitally corrected transposition and Mustard and Senning procedures maintain the right ventricle as the systemic ventricle, and the tricuspid valve is subject to unique hemodynamic stress not typically seen in normal circulation. Surgical treatment of tricuspid valve disease remains the mainstay of therapy; primary catheter-based interventions are uncommon. However, once a tricuspid valve has been replaced with a bioprosthesis, the patient may be a candidate for tricuspid valve-in-valve catheter-based replacement.
Dr. Sommer has conducted physician training for Abbott (PFO) and Boston Scientific (Watchman); has received a research grant from AstraZeneca; is a national co–principal investigator in the ASSURED trial (W.L. Gore); is a local principal investigator in the PREVAIL trial (Boston Scientific); is a local principal investigator in the Conformal LAA Device Trial; and is a national cardiology principal investigator in the Migraine/PFO Trial (W.L. Gore). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received June 15, 2018.
- Revision received October 4, 2018.
- Accepted October 18, 2018.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.